MARKET

MEOBF

MEOBF

Mesoblast
OTCPK
1.390
NaN%
Closed 09:30 10/07 EDT
OPEN
--
PREV CLOSE
1.900
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.900
52 WEEK LOW
1.140
MARKET CAP
1.80B
P/E (TTM)
-31.3063
1D
5D
1M
3M
1Y
5Y
1D
State Street Group Cuts Mesoblast Stake Below Substantial Holder Threshold
TipRanks · 6d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 09/28 00:10
Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches
TipRanks · 09/24 00:30
State Street Group Ceases to Be Substantial Holder in Mesoblast
TipRanks · 09/23 08:57
Jefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)
TipRanks · 08/31 12:16
Analysts Offer Insights on Healthcare Companies: Mesoblast Limited (OtherMEOBF), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Wuxi Biologics (Cayman) (OtherWXIBF)
TipRanks · 08/28 00:20
Mesoblast price target raised to $39 from $35 at Piper Sandler
TipRanks · 08/27 10:45
Mesoblast revenue surges on RYONCIL launch as late‑stage pipeline advances
TipRanks · 08/26 23:52
More
About MEOBF
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd stock information, including OTCPK: MEOBF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEOBF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MEOBF stock methods without spending real money on the virtual paper trading platform.